by Mrudula Kulkarni

2 minutes

Laura Hamill Joins Jazz Pharmaceuticals Board

Laura Hamill elected as new independent director to Jazz Pharmaceuticals' board.

Laura Hamill Joins Jazz Pharmaceuticals Board

Laura Hamill has been elected as a new independent director to the board of directors of Jazz Pharmaceuticals. Ms Hamill, a 35-year pharmaceutical industry veteran, offers the board of the firm extensive executive leadership and worldwide commercial operations experience. The election of Ms. Hamill, which comes after Patrick Kennedy's appointment earlier this year, is indicative of Jazz's ongoing emphasis on Board renewal. In addition to electing Ms. Hamill and Mr. Kennedy, shareholders also re-elected Kenneth O'Keefe and Mark Smith to another term at today's Annual General Meeting.

Ms. Hamill most recently worked as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc. from 2018 to 2019. From 2002 until 2018, Ms. Hamill held many high management positions at Amgen Inc. She held positions as Senior Vice President, U.S. Commercial activities, Vice President, International Marketing and Business Operations in Zug, Switzerland, and Senior Vice President, Intercontinental Region, where she was responsible for managing activities across 26 nations. Ms. Hamill currently serves on the boards of directors of Y-mAbs Therapeutics Inc., Unchained Labs, Inc., and BB Biotech.

"I am impressed by the global talent in the organisation driving the strength of Jazz's business," added Hamill. "I look forward to the opportunity to work alongside my Board colleagues and the company's management to help guide the company's future growth in order to deliver sustained value to our shareholders and meaningful impact for patients."

Peter Grey and Catherine Sohn, Pharm.D., have departed from the Jazz Board, as previously announced. As of today, the board consists of twelve directors, five of whom were appointed in the last five years."I want to thank Cathy and Peter for their outstanding service and dedication to Jazz," said Mr. Cozadd. "They were both important contributors to our team and respected members of the Jazz Board.




Author Profile

Mrudula Kulkarni

Researcher Assistant

Comment your thoughts

Author Profile

Mrudula Kulkarni

Researcher Assistant

Ad
Advertisement

You may also like

Article
Teva Pharmaceutical Welcomes Matthew Shields as Executive Vice President of Global Operations

Mrudula Kulkarni